NCT03840200 - A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

December 7, 2021

Study Completion Date

January 4, 2022

Conditions

Breast CancerProstate CancerOvarian Cancer

Interventions

DRUG

Ipatasertib

Ipatasertib will be administered orally.

DRUG

Rucaparib

Rucaparib will be administered orally.

Trial Locations (17)

2010

Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst

2109

Macquarie University Hospital, Macquarie Park

3144

Cabrini Hospital Malvern, Malvern

19111

Fox Chase Cancer Center, Philadelphia

20089

Azienda Ospedaliera Santa Maria di Terni, Terni

20133

Fondazione IRCCS Istituto Nazionale dei Tumori; S. C. Oncologia Medica 2, Milan

29010

Hospital Universitario Virgen de la Victoria, Málaga

31620

Clínica Universidad de Navarra, Pamplona

35128

Istituto Oncologico Veneto IRCCS, Padua

75246

Mary Crowley Medical Research Center; Oncology, Dallas

92069

California Cancer Associates for Research & Excellence, Inc., San Marcos

08816

Regional Cancer Care Associates LLC, Central Jersey Division, East Brunswick

00144

Istituto Nazionale Tumori Regina Elena IRCCS, Rome

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University, Seoul

06351

Samsung Medical Center, Seoul

08035

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY